Rapid detection of genetic mutations related to a patient's drug metabolism status
AutoGenomics and Gentris Form Strategic Alliance to Launch Clinical Pharmacogenomic Diagnostics to incorporate key pharmacogenomic markers onto an automated molecular diagnostics platform
"Gentris has an established track record in developing pharmacogenomic tests with an clear understanding of the regulatory requirements," noted Fareed Kureshy, President & CEO of AutoGenomics. "This alliance will leverage these strengths and bring pharmacogenomic testing to near patient testing, realizing the true benefits of personalized medicine."
"AutoGenomics has developed a multiplexing platform that has simplified genomic testing through automation," said Michael Murphy, Gentris President & CEO. "Clearly the shared vision of Gentris and AutoGenomics will help to decrease serious adverse drug reactions, which are the fourth leading cause of death and the fifth leading cause of illness in the United States," according to Murphy.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.